Châtillon, France, April 30, 2026DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DBV Technologies has $46.4 million in cash as of September 30, 2024, which is expected to last until Q1 2025. COMFORT Toddlers safety study is set to enroll 300–350 toddlers by Q2 2025, supporting BLA ...

DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash. The disclosure came via a going concern note in the company’s fourth-quarter and full-year ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DBV Technologies S.A. (DBVT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive interim results from its ongoing Open-Label ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s ...